Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669870 | 1.00 | NFE2L2 (0.50) | NFE2L2SMN1; SMN2KMT2ACA12CA1 | |
| SCHEMBL475141 | 0.85 | ALDH1A1 (0.46) | NFE2L2SMN1; SMN2KMT2ACA12CA1 | |
| SCHEMBL8118707 | 0.85 | KMT2A (0.46) | NFE2L2SMN1; SMN2KMT2ACA12CA1 | |
| SCHEMBL1848425 | 0.83 | KMT2A (0.45) | NFE2L2SMN1; SMN2KMT2ACA12CA1 | |
| SCHEMBL931127 | 0.83 | KMT2A (0.41) | NFE2L2SMN1; SMN2KMT2ACA12CA1 | |
| SCHEMBL25434306 | 0.82 | CA1 (0.61) | NFE2L2SMN1; SMN2KMT2ACA12CA1 | |
| SCHEMBL151213 | 0.82 | CA1 (0.61) | NFE2L2SMN1; SMN2KMT2ACA12CA1 | |
| SCHEMBL27753904 | 0.82 | CA1 (0.61) | NFE2L2SMN1; SMN2KMT2ACA12CA1 | |
| SCHEMBL2035810 | 0.81 | L3MBTL1 (0.53) | NFE2L2SMN1; SMN2KMT2ATDP1L3MBTL1 | |
| SCHEMBL2033183 | 0.81 | RPS6KA2 (0.41) | NFE2L2KMT2ACA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979979-A1 | ADDITIVES FOR NON-AQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY USING THE SAME | LG Chem, Ltd. (KR) | 2008-10-15 | — | — | EP | claimed |
| WO-2007083917-A1 | ADDITIVES FOR NON-AQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY USING THE SAME | LG CHEM, LTD. (KR) | 2007-07-26 | — | — | WO | claimed |
| US-20070166609-A1 | ADDITIVES FOR NON-AQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY USING THE SAME | LG CHEM, LTD. (KR) | 2007-07-19 | — | — | US | claimed |
| US-20250361253-A1 | STING AGONIST COMPOUNDS | SUTRO BIOPHARMA INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4536672-A1 | STING AGONIST COMPOUNDS | Sutro Biopharma, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4523755-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| EP-4360713-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN LA ROCHE (CH) | 2024-10-30 | — | — | EP | disclosed |
| CN-118255772-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4389752-A1 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-06-26 | — | — | EP | disclosed |
| EP-4360713-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| CN-117412953-A | Axl inhibitors | 微境生物医药科技(上海)有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-1994029243-A1 | SYNTHESIS OF SUBSTITUTED TRIPHENYLENES, USEFUL AS DISCOTIC LIQUID CRYSTALS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
| US-4855476-A | 3,4-DIBENZYLOXY-5-FLUOROBENZYLCYANIDE FROM 2-FLUORO-6-METHOXYP HENOL | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1989-08-08 | — | — | US | disclosed |
| US-4737504-A | INCREASE BETA-2 ADRENERGIC ACTIVITY WHILE DECREASING BETA-1; CARDIOVASCULAR AND RESPIRATORY DISORDERS | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1988-04-12 | — | — | US | disclosed |
| US-4479901-A | Fluorination of carbanions with N-fluoro-N-alkylsulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-30 | — | — | US | disclosed |
| EP-0080012-A1 | 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0007070-B1 | 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS HAVING DOPAMINE RECEPTOR BLOCKING ACTIVITY | SMITHKLINE BECKMAN CORPORATION (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4265890-A | ANTIPSYCHOTIC, ANTIEMETICS | SMITHKLINE CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| EP-0007070-A1 | 2,3,4,5-Tetrahydro-1H-3-Benzazepines, process for their production and pharmaceutical compositions having dopamine receptor blocking activity | SMITHKLINE BECKMAN CORPORATION (US) | 1980-01-23 | — | — | EP | disclosed |
| US-3976695-A | Halogen substituted α-(aminoalkyl)-3,4-dihydroxybenzyl alcohols | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361253-A1 | STING AGONIST COMPOUNDS | STING1, CGAS, MAVS | NFE2L2 1578/4885SMN1; SMN2 2004/4885KMT2A 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.